CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis

A Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of CBP-201 Monotherapy in Patients With Moderate-To-Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy

This is a Phase 3, randomized, double-blinded, placebo-controlled trial in patients, ≥12 years of age who weigh ≥40 kg, and are diagnosed with moderate-to-severe AD.

Study Overview

• Status: Withdrawn
• Conditions: Atopic Dermatitis
• Intervention / Treatment: Drug: CBP-201; Drug: Placebo

Detailed Description

This study is comprised of a 2- to 6-week (Day-45 to Day 1) Screening Period, a 16-week randomized, double-blind Treatment Period 1, a 36-week Treatment Period 2, and an 8-week follow-up after the last dose of study drug. Therefore, participants will be enrolled in the trial for a maximum of 66 weeks.

• Study Type: Interventional
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Arkansas
    • Little Rock, Arkansas, United States, 72117
      • Connect Investigative Site 4104
  • California
    • Lancaster, California, United States, 93534
      • Connect Investigative Site 4148
  • Florida
    • Miami Beach, Florida, United States, 33162
      • Connect Investigative Site 4123
  • Illinois
    • Flossmoor, Illinois, United States, 60422
      • Connect Investigative Site 4131
    • Rolling Meadows, Illinois, United States, 60008
      • Connect Investigative Site 4140
  • Missouri
    • Hazelwood, Missouri, United States, 63042
      • Connect Investigative Site 4126
  • Nevada
    • Las Vegas, Nevada, United States, 89106
      • Connect Investigative Site 4108
  • Texas
    • Pflugerville, Texas, United States, 78660
      • Connect Investigative Site 4114
  • Virginia
    • Richmond, Virginia, United States, 23233
      • Connect Investigative Site 4106

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

-

• Able to provide written informed consent or assent (as per local law).
• Adults and adolescents of any sex or gender (12 years of age or older)
• Body weight ≥ 40 kg at Screening
• Diagnosis of chronic Atopic Dermatitis as defined according to American Academy of Dermatology Consensus Criteria (Eichenfield 2014), present ≥ 3 year before Screening.

Atopic Dermatitis history with ALL the following disease activity criteria:

1. Involvement of ≥ 10% BSA at Screening and Baseline (Day 1).
2. An EASI score of ≥ 16 at Screening and Baseline (Day 1).
3. An IGA score of ≥ 3 at Screening and Baseline (Day 1).

4. Baseline weekly average of daily PP-NRS ≥ 4 at Baseline (Day1).

   • Participant has applied a Sponsor approved emollient twice a day for at least 14 days before the Baseline Visit and agree to continue at least daily use during study participation.

   • Documented recent history (within 180 days before Screening) of inadequate response to treatment with TCS or topical immunomodulator medication or for whom topical treatments are otherwise medically inadvisable (e.g., important side effects or safety risks).

   • Participants must agree to avoid the use of prohibited AD medications throughout the duration of the study.
   • In the opinion of the Investigator, participant is willing and able to comply with all study visits and study-related procedures.
   • Female patients of childbearing potential who are sexually active with a non-sterilized male partner should have a confirmed negative serum beta-human chorionic gonadotropin test at Visit 1 and agrees to use acceptable forms of birth control.

Exclusion Criteria:

-

No current or past history of:

1. Other active skin diseases (e.g., psoriasis, lupus erythematosus etc.) or skin infections (bacterial, fungal, or viral) that require systemic treatment within 4 weeks of Screening Visit or would interfere with the assessment of AD lesions.
2. History of recurrent herpes herpeticum in the prior 12 months or more than 2 episodes of herpes herpeticum in past 2 years.
3. Non-skin related active infection requiring systemic treatment with parenteral anti-infectives within 30 days or oral anti-infectives within 14 days before the Baseline Visit (Visit 2).
4. Active human immunodeficiency virus (HIV) defined as a confirmed positive anti-HIV antibody test.
5. Tuberculosis requiring treatment within the past 12 months before Screening. Note: Evaluation of tuberculosis will be according to local guidelines as per standard of care.
6. Active Hepatitis B virus (HBV) or hepatitis C virus (HCV).

7. HCV: HCV ribonucleic acid (RNA) detectable in any subject with anti-HCV antibody (HCV Ab).

   •

Participant may not have any of the following conditions:

1. Known primary immunodeficiency or immunocompromised
2. History of malignancy within 5 years before the Screening Visit except for completely treated in situ carcinoma of the cervix or completely treated and resolved basal cell carcinoma of the skin.
3. A helminth parasitic infection diagnosed within 6 months before Visit 1 that has not been treated with or has failed to respond to standard of care therapy.
4. History of chronic alcohol or drug abuse including chronic use of cannabis (e.g., inhalation and/or consumption of marijuana more than once per week) within 12 months before screening.
5. History of attempted suicide or is at significant risk of suicide.
6. History of anaphylaxis after administration of a biologic medication or vaccine.
7. History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, e.g., monoclonal antibody) or to any of the study drug excipients [L-histidine, trehalose, or Tween (polysorbate) 80].

8. Any disorder, including, but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could: affect participant safety, alter the findings of the study or the interpretation of study results, impede the participant's ability to complete the entire duration of the study, or would require frequent bursts of systemic corticosteroids.

   • Participant may not have Prior/Concomitant Therapy as follows:

a. Receipt of live (attenuated) vaccines within 30 days of Baseline (Day 1) NOTE: Receipt of inactive/killed vaccines (e.g., influenza) or mRNA vaccines (e.g., COVID) are permitted provided that they are not given within 5 days before/after any of the study visits.

b. Receipt or donation of any blood product in the 28 days before Baseline (Day 1).

NOTE: Patients who are not willing to abstain from donating blood and/or plasma from Screening and for the 112 days after last dose of study drug should not be enrolled.

•

Participant is unable or unwilling to discontinue current prohibited AD treatments within defined washout windows below and in prohibited medications Section 6.11, as applicable, before Baseline (Visit 2):

1. Systemic JAK inhibitors including but not limited to ruxolitinib, tofacitinib, baricitinib, upadacitinib, abrocitinib and filgotinib within 60 days
2. Lymphocyte depleting agents such as rituximab within 6 months or when lymphocyte counts return to normal whichever is longer
3. Systemic therapy for AD including but not limited to corticosteroids, methotrexate, cyclosporine, azathioprine, phosphodiesterase type 4 (PDE-4) inhibitors, or mycophenolate mofetil within 4 weeks
4. Targeted biologic treatments (as listed in prohibited medication Section 6.11) within 5 half-lives (if known) or 12 weeks, whichever is longer
5. At any time prior to baseline, patient did not respond favorably to previous dupilumab or other anti-IL4Rα or anti-IL-13 treatment (e.g., therapy failure, patient experienced an adverse reaction to treatment)
6. Oral or parenteral traditional Chinese medicine within 4 weeks
7. Topical treatments other than the Sponsor permitted emollient, including but not limited to TCS, TCI, PDE-4, antihistamines, or JAKi within 2 weeks
8. Phototherapy treatment, laser therapy, tanning booth, or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks
9. Use of bleach baths in the prior 2 weeks
10. Topical anti-infectives within 2 weeks

11. Emollients only available by prescription within 2 weeks including those containing ceramide, hyaluronic acid, urea, filaggrin, Vitamin D or Vitamin E, even if not prescribed Prior/Concurrent Clinical Study Experience

    • Receipt of any experimental systemic medications in the 42 days before Baseline (Day 1), or 5 half-lives (if known), whichever is longer.
    • Previous enrollment in a CBP-201 treatment protocol and having received at least 1 dose of active study drug.
    • Concurrent enrollment in another trial where the patient is receiving an experimental intervention.

Have the following laboratory abnormalities at Screening:

1. Hemoglobin ≤ 10 g/dL
2. Platelet count < 100,000 cells/µL
3. Eosinophil count > 1500 cells/ µL
4. Total creatine phosphokinase (CPK) > 3 times the upper limit of the normal (ULN)
5. Alanine aminotransferase (ALT) ≥ 2.0xULN
6. Aspartate aminotransferase (AST) ≥ 2.0x ULN
7. Total Bilirubin ≥ 1.5x ULN (an isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated, and the direct bilirubin is < 35% or if the participant has known Gilbert's Syndrome)

8. Alkaline Phosphatase >2x ULN

   • Abnormal ECG at screening per investigator assessment.
   • Major surgery, requiring anesthesia, within 6 weeks before Baseline (Day 1), or planned in-patient surgery or hospitalization during study participation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: [Treatment Period 1]Group 1-Dose1; CBP-201 600 mg (4 mL) SC on Day 1 (Week 0 visit) visit followed by 300 mg (2 mL) SC Q2W starting at Week 2 with the last dose at Week 14.	Drug: CBP-201; CBP-201 subcutaneous(SC) injection
Placebo Comparator: [Treatment Period 1]Goup 2-Placebo1; Placebo (4 mL) SC on Day 0 (Week 0) visit followed by placebo (2 mL) SC Q2W starting at Week 2 with the last dose at Week 14	Drug: Placebo; subcutaneous(SC) injection
Experimental: [Treatment Period 2] Group 1-Dose2; CBP-201 300 mg SC Q2W starting at Week 16 with the last dose at Week 50 Treatment Period 2 (Group 1 Dose 1 responder pts that rerandomize to Dose 2, Dose 3, or PBO 2)	Drug: CBP-201; CBP-201 subcutaneous(SC) injection
Experimental: [Treatment Period 2] Group 1-Dose3; CBP-201 300 mg SC Q4W starting at Week 16, alternating with placebo SC Q4W starting at Week 18 with the last dose of CBP-201 at Week 48 and placebo at Week 50	Drug: CBP-201; CBP-201 subcutaneous(SC) injection
Placebo Comparator: [Treatment Period 2] Group 1-Placebo2; Placebo Q2W SC starting at Week 16 with the last dose at Week 50	Drug: Placebo; subcutaneous(SC) injection
Placebo Comparator: [Treatment Period 2] Group 2-Placebo; PBO 1 pts responders that continue PBO 1	Drug: Placebo; subcutaneous(SC) injection
Experimental: [Treatment Period 2] Group 3-Dose; Dose 1 and PBO 1 Non-responders, and Group 1 and 2 Non-responders that get open-label Dose 4 or 5 (LD 300 mg or 600 mg, biweekly 300 mg thereafter)	Drug: CBP-201; CBP-201 subcutaneous(SC) injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Investigator Global Assessment(IGA)(0-1)	The proportion of participants whose IGA score is 0-1 and decreased by ≥2 points	Baseline to Week16
EASI-75	The proportion of participants achieving EASI-75	Baseline at Week 16

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Peak Pruritus Numerical Rating Scale（PP-NRS）(in the US)	The proportion of participants achieving an improvement (reduction) of ≥4 on Peak Pruritis numeric rating scale (PP-NRS)	Baseline at Week16
Investigator Global Assessment(IGA)(0-1) (outside of the US)	Proportion of participants achieving an IGA score of 0 or 1 and a 2-grade improvement in IGA	Baseline at Week16
Change in Peak Pruritus Numerical Rating Scale（PP-NRS）(outside of the US)	Proportion of participants achieving an improvement (reduction) of ≥4 on PP-NRS	Baseline at Week16
Scoring Atopic Dermatitis(outside of the US)	Change in Scoring Atopic Dermatitis (SCORAD)	At Week16
Dermatology Life Quality Index(outside of the US)	Change in Dermatology Life Quality Index (DLQI) score	Baseline at Week16
EASI-90	Proportion of participants achieving 90% reduction in EASI score	Baseline at Week16

Collaborators and Investigators

• Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.

Study record dates

Study Major Dates

• Study Start (Anticipated): December 1, 2022
• Primary Completion (Anticipated): August 1, 2024
• Study Completion (Anticipated): July 1, 2025

Study Registration Dates

• First Submitted: November 6, 2022
• First Submitted That Met QC Criteria: November 6, 2022
• First Posted (Actual): November 14, 2022

Study Record Updates

• Last Update Posted (Actual): March 21, 2023
• Last Update Submitted That Met QC Criteria: March 19, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Keywords: Eczema; allergy; allergic dermatitis; pruritis; type 2 inflammation
• Additional Relevant MeSH Terms: Skin Diseases; Immune System Diseases; Hypersensitivity, Immediate; Genetic Diseases, Inborn; Skin Diseases, Genetic; Hypersensitivity; Skin Diseases, Eczematous; Dermatitis; Eczema; Dermatitis, Atopic
• Other Study ID Numbers: CBP-201-WW004; 2022-000999-19 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No